The UN is preparing to review nicotine for potential international drug scheduling — a process that could lead to a vote on global controls by 2028. The move was triggered by the Pacific island nation of Palau, which formally asked the World Health Organization to assess whether nicotine belongs on the list of controlled psychotropic substances.

This isn't about cigarettes. Those already have an "ironclad" health case for banning, as former WHO head Gro Harlem Brundtland put it in 2000: "a cigarette is the only consumer product which when used as directed kills its consumer." The focus here is tobacco-free nicotine products — vapes and nicotine pouches using synthetic nicotine that have surged in popularity while regulation lagged behind.

What happened

On June 10, 2026, the Republic of Palau submitted a formal notification to the UN Secretary-General under Article 2 of the 1971 Convention on Psychotropic Substances. The notification requests that the WHO Expert Committee on Drug Dependence (ECDD) conduct a critical review of nicotine.

Palau — a tiny archipelago in the Pacific with a population under 20,000 — has already banned vapes domestically. The country is now pushing for international action, arguing that more than a billion people are dependent on nicotine globally and that new products are outpacing regulatory responses.

Nature reported that Palau wants nicotine scheduled under the 1971 convention, which governs psychotropic substances ranging from sleep medications to psychedelics.

What's actually under review

The WHO ECDD will conduct a scientific assessment of nicotine — its dependence potential, health effects, and public health impact. The committee then makes a recommendation to the UN Commission on Narcotic Drugs, which would vote on whether to place nicotine under international control.

The review forces a thorny question: Is addiction itself harmful, even without the cancer and lung disease risks of combustible tobacco? Synthetic nicotine products don't carry the same mortality risks as smoking, but they do create dependence. Palau's supporting scientific dossier, submitted alongside the notification, makes the case that the scale of nicotine dependence justifies international oversight.

Why this matters for the pouch market

A global scheduling decision would be the nuclear option for the nicotine pouch industry. These products already face a patchwork of national regulations — some countries treat them like tobacco, others like consumer goods, some have banned them outright. International drug scheduling would override all of that.

The case for restriction: highly addictive products can reveal consequences later, even when they seem safer at first. The case against: these products exist largely because of smoking's harms, and restricting them could push users back toward combustibles.

What happens next

The WHO ECDD review process typically takes 18-24 months. A vote by the UN Commission on Narcotic Drugs would likely come in 2028. For now, nothing changes for consumers or retailers — but the review itself signals that the international community is taking nicotine addiction seriously as a standalone public health issue, separate from combustible tobacco.

The WHO has separately warned countries not to follow Sweden's permissive approach to nicotine pouches, publishing a report in May 2026 that accused the industry of targeting youth with sweet flavors and influencer marketing.

---

SOURCES:

• Republic of Palau official site: Notification on the international review of nicotine (10 June 2026)
• WHO FCTC: Palau Calls for Global Review of Nicotine as New Products Expand (24 June 2026)
• Nature: Should nicotine be regulated like a narcotic? A Pacific nation makes the case (17 June 2026)
• WHO: WHO warns nicotine pouch brands targeting youth as sales surge (15 May 2026)
• The Guardian: The Guardian view on nicotine: we shouldn't buy the idea of addiction without harm (21 June 2026)

---

Compare nicotine pouch prices across retailers at PouchFinder.